Japanese CRO EPS To Develop And Market Drugs In China
This article was originally published in PharmAsia News
Executive Summary
Japanese CRO EPS has entered the drug development business in China. The company has signed an agreement with Japanese mid-sized drug companies to market two drugs in China. Chinese clinical trials will be starting this year and the company aims for approvals by March 2010. EPS also plans to license five more drugs to market in China, and invest ¥100-¥200 million to start the clinical trials. EPS entered China in 1999, and the company has since established a Beijing EPS subsidiary to support new drug development. (Click here for more - Japanese language
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.